company background image
2181 logo

Mabpharm SEHK:2181 Stock Report

Last Price

HK$0.44

Market Cap

HK$1.8b

7D

2.3%

1Y

17.3%

Updated

13 May, 2025

Data

Company Financials

Mabpharm Limited

SEHK:2181 Stock Report

Market Cap: HK$1.8b

2181 Stock Overview

A biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. More details

2181 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Rewards

Earnings have grown 1.7% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the Hong Kong market

Has less than 1 year of cash runway


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Mabpharm Limited Competitors

TOT BIOPHARM International

SEHK:1875

HK$1.4b

Qyuns Therapeutics

SEHK:2509

HK$2.5b

Cutia Therapeutics

SEHK:2487

HK$2.0b

ImmuneOnco Biopharmaceuticals (Shanghai)

SEHK:1541

HK$2.6b

Price History & Performance

Summary of share price highs, lows and changes for Mabpharm
Historical stock prices
Current Share PriceHK$0.44
52 Week HighHK$0.94
52 Week LowHK$0.25
Beta0.75
1 Month Change-10.20%
3 Month Change51.72%
1 Year Change17.33%
3 Year Change-35.29%
5 Year Change-65.89%
Change since IPO-63.64%

Recent News & Updates

Is Mabpharm (HKG:2181) Using Too Much Debt?

Mar 27
Is Mabpharm (HKG:2181) Using Too Much Debt?

There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump

Feb 19
There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump

Recent updates

Is Mabpharm (HKG:2181) Using Too Much Debt?

Mar 27
Is Mabpharm (HKG:2181) Using Too Much Debt?

There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump

Feb 19
There's Reason For Concern Over Mabpharm Limited's (HKG:2181) Massive 45% Price Jump

Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel

Dec 22
Investors Don't See Light At End Of Mabpharm Limited's (HKG:2181) Tunnel

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14
Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24
More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Oct 20
Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Jan 18
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Oct 07
Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28
Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03
Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27
We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09
Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Shareholder Returns

2181HK BiotechsHK Market
7D2.3%-6.4%2.1%
1Y17.3%38.8%12.6%

Return vs Industry: 2181 underperformed the Hong Kong Biotechs industry which returned 36.6% over the past year.

Return vs Market: 2181 exceeded the Hong Kong Market which returned 13% over the past year.

Price Volatility

Is 2181's price volatile compared to industry and market?
2181 volatility
2181 Average Weekly Movement29.7%
Biotechs Industry Average Movement13.7%
Market Average Movement8.1%
10% most volatile stocks in HK Market15.5%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 2181's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 2181's weekly volatility has increased from 16% to 30% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018315Hao Wangwww.mabpharm.cn

Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People’s Republic of China. The company offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment of ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease in adults and pediatric patients aged above 6 years old, fistula Crohn’s disease, and psoriasis. It also develops CMAB807/CMAB807X that has completed Phase III clinical trial for the treatment of osteoporosis, tumor bone metastasis, and giant-cell tumor of bone; CMAB819 that has completed Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis that is in Phase I clinical trial.

Mabpharm Limited Fundamentals Summary

How do Mabpharm's earnings and revenue compare to its market cap?
2181 fundamental statistics
Market capHK$1.81b
Earnings (TTM)-HK$138.49m
Revenue (TTM)HK$279.51m

6.5x

P/S Ratio

-13.1x

P/E Ratio

Is 2181 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2181 income statement (TTM)
RevenueCN¥258.23m
Cost of RevenueCN¥38.83m
Gross ProfitCN¥219.39m
Other ExpensesCN¥347.34m
Earnings-CN¥127.95m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.031
Gross Margin84.96%
Net Profit Margin-49.55%
Debt/Equity Ratio297.0%

How did 2181 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/13 05:40
End of Day Share Price 2025/05/13 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mabpharm Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yue-Kwong LuiJefferies LLC